Archive 1995–2023

Contemporary treatment of acute ischemic stroke focuses on drugs inducing early reperfusion of occluded arteries leading blood to the brain. Thrombolysis with recombinant tissue plasminogen activator (rt-PA, alteplase) is the only agent proved to be effective in clinical trials and having a considerably low rate of adverse effects if introduced within 3 hours of stroke symptom onset. Recently studies on expanding the therapeutic window, what could result in increasing the number of treated patients and inducing rt-PA efficacy are being performed. Clinical trials and our experience confirm it's higher efficacy compared to other known stroke treatments.